- £161m investment including £29m capital project and creation of 540 jobs
- Next generation medical diagnostics manufacturing facility
- World leading R&D into conditions such as cancer, stroke, heart disease, neurodegenerative disorders, STIs, aspirin resistance, sepsis and respiratory infections
“This investment and expansion reinforces our dedication to improving health worldwide…”
Global medical diagnostics company Randox, has unveiled its plans for a futuristic manufacturing and R&D facility in the UK. The £161 million project, which includes a £29 million capital investment for the redevelopment of the site, will accelerate the development of new products into a wide range of clinical needs, such as various cancers, stroke, heart disease and neurodegenerative disorders, through more efficient, high specification manufacturing and the provision of state-of-the-art R&D laboratories.
Randox leads in the research, development and manufacture of pioneering medical tests and cutting edge diagnostic equipment, with customers in clinical, toxicology, veterinary and food safety markets in more than 145 countries.
The award-winning biotechnology firm, with headquarters in Crumlin, County Antrim, recently purchased the former British Army base at Massereene, in Antrim town, which will be redeveloped to house the new centre of manufacturing and R&D, now renamed, Randox Science Park.
Randox Science Park will become the company’s prime manufacturing site, complementary to its manufacturing operations in Manchester, Republic of Ireland, India and the USA. Randox has a range of more than 2000 products, including advanced diagnostic tests, quality control sera, analysers and the company’s revolutionary BioChip Array Technology; many of which will be produced at this next generation facility.
This considerable investment will also lead to the creation of 540 high value job opportunities, over the next four years.
In addition, the site will feature a Transformative Healthcare Centre from the Randox Health division; giving the public direct access to Randox’s ground-breaking tests, as well as offering private GP appointments and specialist clinics, run by some of the UK’s chief medical consultants.
At a launch event today, Randox showcased its plans for Randox Science Park. Guests including Northern Ireland’s First Minister, Peter Robinson, Deputy First Minister, Martin McGuinness and Enterprise Minister, Arlene Foster, were briefed on the company’s impact on global health and vision for the future.
Speaking at the event, Randox Managing Director, Dr Peter FitzGerald said:
“The creation of Randox Science Park is fundamental to Randox meeting the health challenges facing populations across the world. We are an innovation led company, focusing more than 30 years of skills and experience on delivering accurate, rapid and quality diagnostics across a range of clinical disciplines; from stroke and heart disease, to cancer, neurodegenerative disorders, respiratory infections and so on. We must continue innovating, through our people, through our knowledge and through our technology; Randox Science Park gives us the platform we need to do this.
“Randox innovation underpins our achievements, allows us to diversify, allows us to target fresh markets and fuels our exports and Randox Science Park will be at its core. This investment and expansion reinforces our dedication to improving health worldwide and our commitment to the UK economy. It is about the future of diagnostic medicine, we are beginning 2015 as we mean to continue.”
The expansion includes the creation of manufacturing, scientific and engineering opportunities on a major scale, as well as business support posts; the investment will also grow Randox’s sales and marketing capabilities. In addition, the 540 new jobs, with an average salary of £30k per year will generate £16.2 million in annual salaries, representing a significant boost to the UK economy.
The company said it was already engaging with universities across the UK, to access high calibre graduates for the world class opportunities at Randox Science Park.
Regional development agency, Invest Northern Ireland is supporting the £29m Randox capital redevelopment of the site, with an investment of £4.7 million.
Leading clinical diagnostics firm Randox Laboratories goes head to head with some of the biggest brands in the UK, as it competes for the title of ‘National UK Champion’ in the European Business Awards 2015.
Randox, having already faced stiff competition from across the UK to be shortlisted as a National Champion, will now face the public vote and are asking you to put health at the frontline by supporting them.
Randox will be judged by the public from a company video which gives a powerful and inspiring insight into the story of Randox.
From its headquarters in Crumlin Co Antrim, Randox has grown into an international success story, at the frontline of improving health in conditions such as stroke, dementia, diabetes, heart disease, STI’s and respiratory infections through earlier and more accurate diagnosis.
Every year a staggering 350 million people – 5% of the world’s population – are diagnosed with Randox products. Randox supplies 10% of the world’s cholesterol tests, and 8% of all clinical chemistry tests undertaken globally: the chances are if you’ve ever had blood taken by a doctor it’s been assessed using a Randox product.
Randox aren’t standing still: driven by innovation and a commitment to saving lives, Randox currently has more clinical diagnostic tests in development than any other company in the world.
Why vote for Randox? Dr Peter Fitzgerald, Managing Director of Randox says:
“Randox’s key driver is to save lives. Our raison d‘etre is to improve health not just here in Northern Ireland but right across the world. Our success is built on world-class, innovative products which enable earlier, more accurate diagnosis. In doing so we improve the quality of life, enhance the efficiency of healthcare and save lives, globally.”
Randox will compete against other UK shortlisted Champions for the public vote. The company with the most votes will be named the UK’s ‘National Public Champion’ on 3rd March 2015. From this, National Champions will have the opportunity to compete with winners from across Europe to earn the highly acclaimed title of ‘European Public Champion’ at a glittering Awards Gala event in May 2015.
Global biotechnology firm Randox, is announcing that recruitment for the expansion of its facility in Dungloe is now underway. In October the company laid out its vision for Randox Teoranta, its cutting-edge life science and engineering centre, which included a major investment of €25m in the site and a jobs boost of almost 500 posts to be filled by 2020.
The first wave of recruitment for #Dungloe2020 has just begun, with the initial focus on electrical, mechanical and software engineers as Dr Peter FitzGerald, Randox MD explains:
“We are very pleased that the recruitment process is now open for the first of the #Dungloe2020 positions. At the moment, we are keen to hear from those in life sciences, medical device engineering and software; with a particular focus on Software developers and testers, embedded software engineers, those with backgrounds in mechanical design as well as electronic & electrical engineers.
Randox Teoranta is a next generation life-sciences and engineering research and manufacturing centre, the site of pioneering research into conditions impacting human health such as alzheimer’s and diseases of the kidneys and liver. We hope to encourage scientists and engineers returning for Christmas, to consider returning for good to pursue world class careers at home.”
Stiofán Ó Cualáin, CEO, Údarás na Gaeltachta, says they are backing the campaign:
“We are delighted to hear that Randox Teoranta is now commencing its recruitment campaign following the company’s recent announcement of its expansion plans at its facility in An Clochán Liath. Údarás na Gaeltachta, are pleased to be able support Randox Teo. in this recruitment drive. The people that will be employed in these new jobs will play an important role in the growth and continued development of Randox Teoranta. and we wish the company every success with their campaign.”
Randox Teoranta is holding a ‘drop-in’ morning, Wednesday 24th December during the hours of 0900-1200 for anyone interested in the career opportunities available. Representatives from the company will be happy to discuss the #Dungloe2020 expansion and recruitment.
- New STI awareness campaign infects digital and social media
- ‘Mockumentary’ promotes revolutionary new STI home test
- Thousands caught out by spoof STI and sniffer dog squad
- Leading sexual health charity praises timing of campaign as Christmas Party season kicks in
British biotechnology company Randox Laboratories, continues to break new ground, with a spoof documentary to promote its home STI test, Confidante. The award winning firm, recognised internationally for its leading diagnostic technologies, is proving that it is also ahead of the curve when it comes to promoting its products.
Thousands have been caught out by the ‘mockumentary’ which follows the officers and dogs of the STI Detection unit as they sniff out undetected STIs around the UK.
The film, which shows unsuspecting punters outed in public by sniffer dogs Radar, Frisbee and their handlers, ends with an invitation to ‘check your privates in private’ with the Confidante test. The light-hearted strategy is designed to prompt 25-34 year olds to think about their sexual health and get tested.
Dr Peter FitzGerald, Managing Director of Randox Laboratories, said:
“So far, ten thousand people a day are watching the mockumentary, we expect this to grow as the campaign continues. For us it is ultimately about improving health, raising awareness of STIs and encouraging people get tested, we’ve opened up what can be a taboo subject and have done so with humour!
Every day one million people across the world are infected with an STI and at home incidents are continuing to soar – in the UK we are seeing worrying levels of chlamydia, gonorrhoea and syphilis in particular; we want people to take their sexual health seriously and regular testing is a key part of that”.
Sexual health charity FPA has applauded the timing and effectiveness of the campaign. Natika Halil, director of health and wellbeing, said:
“This has clearly created something of a talking point around STIs, which is particularly important in the run up to Christmas and New Year parties as we know people are less likely to think of infections after they have been drinking.
If you have sex without a condom then you are at risk of getting an STI, and not everyone who has an infection has signs or symptoms – so it’s possible to pass it on without realising.”
The infectious digital content has been produced Randox Marketing and creative agency Langland. Randox Marketing Manager, Chris Henry said they wanted something that would start people talking about STIs:
“Our goal was to engage a whole new audience of potential customers who may be too embarrassed to take their sexual health seriously. We believe this campaign does exactly that, communicating the shock of being exposed in public, but doing it with humour, in a way people can engage with without feeling they are publically declaring they have an STI.”
Confidante is the world’s first STI home test kit, to detect 10 common STIs and can be used in the privacy of the home. It uses Randox’s unique Biochip Array Technology, with results delivered within 7 working days, confidentially, via a nurse specialist, either by phone or email. Advice, GP appointments, treatments are available through the Randox Healthcare division, Randox Health.
- UK-based diagnostics firm supporting call for responsible use of antibiotics in conjunction with European and International Antibiotics Awareness initiatives
- New molecular diagnostic multiplex assays hold the key to first-time, accurate diagnosis of infectious diseases
- Assays have the power to diagnose primary, secondary and asymptomatic co-infections to inform appropriate antibiotic prescribing
UK-based diagnostics company, Randox Laboratories, is supporting the call for patients and prescribers to ‘resist and desist’ antibiotic use in the fight against antimicrobial resistance this European Antibiotics Awareness Day. Coinciding with international awareness weeks in Australia, Canada and the USA, the concerted efforts of health authorities around the world to curb the spread of antimicrobial resistance is testimony to the global reach of the issue.
Now declared a ‘major threat’ by the World Health Organisation, Randox has been working at the forefront of this global challenge to deliver effective diagnostic solutions to arm against this growing problem. Developed over two decades of research and an investment of £200m, Randox’s innovative Biochip Array Technology (BAT) is the latest weapon in the fight against antimicrobial resistance, with the ability to simultaneously detect multiple pathogens in a single test for rapid and accurate diagnosis.
Randox’s range of molecular assays within infectious disease enable the detection of primary, secondary and asymptomatic co-infections for a more comprehensive understanding of the drivers of infection in individual patients. The Randox STI Multiplex Array simultaneously detects up to 10 pathogens from a single patient sample, whilst the Randox Respiratory Multiplex Array rapidly screens for 22 bacterial and viral upper and lower respiratory tract infections, with same day result reporting, for rapid diagnosis.
As Randox Managing Director Dr Peter FitzGerald CBE FREng explains, screening for all potential pathogens in infectious disease is vital in ensuring accurate diagnoses can be made; “Even after a confirmed diagnosis, many patients who haven’t been tested for a wider range of pathogens may harbour co-infections, impeding the effectiveness of therapeutic treatment and prolonging exposure to infection.
“Through a more comprehensive screening strategy at initial presentation, a complete patient profile can be obtained which will give clinicians greater understanding of the working of the disease and allow them to diagnose and prescribe correctly, ruling in or out the need for antibiotics, and helping to control their appropriate use.”
Antibiotic resistance has largely been fuelled by patient and prescriber overreliance on using antibiotics to treat disease. Once considered to be ‘magic bullets’ for curing infections, antibiotics are now firing blanks as they become ineffective against many common and treatable infectious diseases, such as the sexually transmitted infection, Neisseria gonorrhoeae, and respiratory tract infections such as staphylococcus aureus and streptococcus pneumoniae, which have been shown to be acquiring increasing levels of resistance to antibiotic treatment.
“First-time, accurate diagnosis of infection through molecular testing is key to treating infections correctly. The availability of these assays provides a powerful weapon in the fight against antimicrobial resistance and we would encourage health providers around the world to utilise this technology to help curb the spread of the problem.”
For more information visit Randox: www.randox.com.
County Antrim biotechnology firm Randox Laboratories, celebrated across the globe for its ground-breaking diagnostics has welcomed two famous faces, also recognised internationally…
The award winning firm, which has recently acquired the former army base at Massereene, has been putting the ‘A-list’ in Antrim, opening up the 42 acre site to actors Jamie Dornan, Gillian Anderson and the rest of the cast and crew of BBC2’s hugely successful series ‘The Fall’.
Parts of the site were transformed into a police station, custody suite and forensics laboratory, for filming of Season 2. David McCann of Randox who worked with the production team, said it was surreal seeing the well-known actors on the set:
“It was a fantastic experience to see stars like Jamie Dornan and Gillian Anderson in action on the set. The wider film crew were great to work with and very courteous to all involved. I believe Jamie liked to wind down with a kick about with the crew after filming. I’m happy he didn’t break any of the windows!”
Randox was called into kit out the forensics laboratory and even provided filming extras, Human Resources Executive, Hannah Hutchinson, was one of them:
“It was a great experience, I was asked to play the part of a lab technician – but I wasn’t nervous because everyone was really nice. Gillian Anderson is so professional, it was terrific to watch. I’m really looking forward to the new series – might even catch a glimpse of myself”.
Randox Laboratories owner and managing director Dr Peter FitzGerald was delighted to provide this location for the BBC Two production and hopes to work with similar projects in the future:
“Randox is an innovative, progressive company which is proud to support the growing Northern Ireland film and TV industry. We are pleased to see big production companies coming here to film, it can only be good news for Northern Ireland. We have had location scouts come to view our new site in Antrim and indeed our lands around the lough shore, but all I can say for now, is watch this space!”
Season 2 of ‘The Fall’, will air on BBC Two in November.
I knew Lord Ballyedmond for many years. When I was endeavouring to start Randox Laboratories in the early 1980’s I went to him for advice. He was of great help to me in the early years of Randox. Eddie and I would frequently discuss business issues and the challenges of managing international business in Northern Ireland. I had great admiration for his courage and enterprise; he will be sadly missed.
Eddie Haughey played an integral part in contributing to economic development in Northern Ireland and to our constantly expanding biotechnology sector. His willingness to invest heavily in innovation and his tireless entrepreneurial efforts to create and grow Norbrook Laboratories into a global success has been an inspiration to businesses operating in the sector across the world. My thoughts are with his family, friends and his staff at Norbrook at this very sad time.
This appointment is of strategic importance in Randox’s plans to increase its market presence in the United States. As part of this Randox is committed to increasing its on the ground leadership and customer support network, with a view to significantly expanding its US market share.
Schaefering brings a wealth of experience to Randox from a career spanning more than 20 years in the industry. He joins Randox from Bio-Rad where he was National Account Manager handling the negotiation and contract management for several GPOs and key accounts including Quest Diagnostics, MedAssets and Premier.
Moving to Randox, Schaefering said:
In today’s healthcare climate, labs are increasing looking for opportunities: opportunities to increase productivity; to be more efficient; to realize labor savings, but without sacrificing on quality. Randox brings opportunity and quality that has largely been missing in the US until now. With QC solutions that are increasingly regarded as the highest quality and most accurate available globally, Randox stands apart from the competition.
Randox Chief Customer Officer, David Brown said:
“Offering first-class customer support is one of the fundamental tenets on which Randox operates. As we grow our customer base in the US we are committed to also growing our customer support network. John Schaefering’s appointment is a key step to ensure our US customers have access to on the ground assistance as and when they need it.”
Randox has had the US market in its sights since 2010, when it opened its 33,000ft² US Headquarters in West Virginia following a multimillion dollar investment. The company’s determination to grow its US market share was reasserted earlier this year when it announced plans to expand its West Virginia HQ into a key manufacturing facility, significantly expanding the company’s capabilities Stateside.
Randox recently announced that it’s won a major supplier agreement with leading healthcare supply chain company Novation, meaning its third party quality control products will now be readily available to hospital organizations throughout the US.